Decursin

Decursin is a pyranocoumarin compound isolated from the root of Angelica gigas Nakai that exerts anticancer, neuroprotective, and cardiovascular effects. Its primary mechanisms involve inhibition of the PI3K/Akt/mTOR signaling cascade, induction of apoptosis, and suppression of NF-κB-driven inflammation.

Origin & History

Decursin is a naturally occurring pyranocoumarin compound (C₁₉H₂₀O₅, molecular weight 328 Da) isolated primarily from the roots of Angelica gigas Nakai (Korean angelica), a plant native to Korea and China. It is extracted using solvent-based methods such as methanol or ethanol extraction of dried roots, followed by chromatographic purification, typically yielding 0.1-1% concentration in dry root weight.

Historical & Cultural Context

While decursin itself is not explicitly documented in historical texts, it derives from Angelica gigas roots, used for over 1,000 years in Traditional Korean and Chinese Medicine as 'Danggwi' or 'Dong Quai' for women's health, menstrual regulation, anemia, and blood circulation. Traditional preparations involved decoction or powdering of roots for oral consumption.

Health Benefits

• Anti-cancer properties: Preclinical studies show decursin induces G1 cell cycle arrest and apoptosis in prostate, breast, colorectal, and lung cancer cells (PMID 15705905, 39337425) - evidence limited to laboratory studies
• Cardiovascular protection: Reduces endothelial-to-mesenchymal transition and oxidative stress in cardiac models at 10-50 μM concentrations (PMC12481280) - preliminary animal/cell evidence only
• Anti-inflammatory effects: Inhibits multiple inflammatory pathways including PI3K/AKT/NF-κB signaling (PMC12481280) - based on in vitro research
• Estrogen modulation: Blocks ERα nuclear translocation and suppresses estrogen-stimulated genes in breast cancer cells (PMC2246173) - cell culture evidence only
• Antioxidant activity: Mitigates ROS-mediated stress and ER stress pathways (PMID 39337425) - demonstrated in laboratory models only

How It Works

Decursin inhibits the PI3K/Akt/mTOR pathway, reducing phosphorylation of downstream survival proteins and triggering G1-phase cell cycle arrest via upregulation of p21 and p27 cyclin-dependent kinase inhibitors. It suppresses NF-κB nuclear translocation, lowering transcription of pro-inflammatory cytokines such as TNF-α and IL-6. Additionally, decursin activates caspase-3 and caspase-9 to initiate intrinsic apoptosis and reduces androgen receptor (AR) expression, which is particularly relevant in androgen-sensitive prostate cancer cells.

Scientific Research

Clinical evidence for decursin in humans is extremely limited, with only one small pharmacokinetic study (n=12 healthy adults) administering ~4.5 mg decursin equivalents showing rapid absorption and 24-hour detection with no adverse events (PMID 25695490). No randomized controlled trials, meta-analyses, or Phase II/III trials have been completed, with all therapeutic evidence remaining at the preclinical stage in cell cultures and animal models.

Clinical Summary

The majority of decursin research consists of in vitro cell-line studies and rodent models; no large-scale human randomized controlled trials have been published as of 2024. Preclinical studies demonstrate dose-dependent apoptosis in LNCaP prostate cancer cells and MCF-7 breast cancer cells, with IC50 values typically in the 10–50 µM range (PMID 15705905). Animal studies in murine colorectal and lung cancer models report significant tumor volume reduction at oral doses of 10–50 mg/kg, but bioavailability challenges limit direct translation to human dosing. One small pilot human study using an Angelica gigas extract suggested tolerability, but isolated decursin pharmacokinetics and efficacy in humans remain insufficiently characterized.

Nutritional Profile

Decursin is a pure isolated bioactive coumarin compound (pyranocoumarin class), not a whole food ingredient, and therefore has no conventional macronutrient, micronutrient, vitamin, mineral, or fiber profile. Molecular formula: C19H21NO5, molecular weight: 347.37 g/mol. As an isolated compound, it is assessed by its bioactive concentration rather than nutritional composition. Preclinical studies utilize concentrations of 10–50 μM in cell and animal models. Natural source concentration: Decursin is found in the roots of Angelica gigas Nakai at approximately 1–5% dry weight of the root extract, with some preparations reporting up to 8 mg/g in standardized extracts. It co-occurs with the related compound decursinol angelate in roughly comparable amounts. Oral bioavailability is limited due to rapid hydrolysis to decursinol (its active metabolite) under alkaline intestinal conditions and hepatic first-pass metabolism; peak plasma concentrations in rodent studies occur at 30–60 minutes post-oral administration. Lipophilicity (logP approximately 2.8) influences tissue distribution. No protein, carbohydrate, fat, or micronutrient content is applicable, as this is a purified phytochemical rather than a food matrix.

Preparation & Dosage

No clinically validated dosages exist due to lack of human efficacy trials. The only human study used ~4.5 mg decursin/decursinol angelate equivalents as a single oral dose. Preclinical studies use 10-100 μM in cell cultures and 5-20 mg/kg in rodent models. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other coumarins, green tea catechins, curcumin, resveratrol, quercetin

Safety & Interactions

Decursin is generally well tolerated in animal studies at tested doses, but human safety data are very limited and no established safe upper limit has been defined for supplemental use. As a coumarin derivative, decursin may theoretically potentiate anticoagulant medications such as warfarin by inhibiting CYP2C9-mediated metabolism, warranting caution in patients on blood thinners. Its inhibition of CYP3A4 in vitro raises the possibility of interactions with drugs metabolized by this enzyme, including certain statins, immunosuppressants, and calcium channel blockers. Decursin is not recommended during pregnancy or lactation due to the absence of safety data and the known uterine-stimulating properties of Angelica species.